# Ferroptosis Findings

### Why ferroptosis matters

Ferroptosis is an **iron-dependent regulated cell-death pathway** driven by lipid peroxidation.

It is distinct from apoptosis, autophagy, and necroptosis.

This matters because some cancers that resist apoptosis may still remain vulnerable to ferroptosis.

### The core ferroptosis axis

Ferroptosis is restrained by a defence system built around:

* **SLC7A11 / System Xc-** for cystine import
* **glutathione (GSH)** synthesis
* **GPX4** to neutralise lipid peroxides
* upstream **Nrf2** signalling

If that defence collapses, lipid peroxides accumulate and the cell can undergo ferroptotic death.

### How berberine may induce ferroptosis

Berberine appears to hit this system at more than one point.

Reported mechanisms include:

* downregulation of **SLC7A11**
* depletion of intracellular **GSH**
* suppression of **GPX4**
* indirect weakening of the pathway through **Nrf2 suppression**

That combination can make tumour cells less able to buffer lipid oxidative damage.

### Cancer models of interest

Preclinical ferroptosis findings have been reported in:

* **oral cancer** models
* **non-small-cell lung cancer** models
* **triple-negative breast-cancer** models

The NSCLC work is especially interesting because berberine has also been studied in combination with ferroptosis-inducing strategies.

### Why this matters in resistant disease

Many aggressive tumours evade treatment by blocking apoptosis.

Ferroptosis bypasses that route.

That makes berberine's ferroptosis signal especially relevant in resistant disease settings such as TNBC, NSCLC, and other high-stress tumours.

### Important context

Berberine's ferroptosis effect appears **context-dependent**.

In non-cancer tissue, berberine has also shown the opposite pattern in some models, helping protect cells through Nrf2-linked antioxidant signalling.

That fits the broader pattern of tumour selectivity rather than a simple one-direction effect.

### Practical interpretation

Berberine may matter here not because it is a pure ferroptosis drug, but because it weakens several ferroptosis-defence systems at once.

That gives it potential value in apoptosis-resistant cancers and in combination strategies designed to increase oxidative pressure.

The evidence is still preclinical.

### Where to Go Next

* [Berberine in Oncology Overview](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology.md)
* [Evidence Summary](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/evidence-summary.md)
* [Anticancer Mechanisms](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/anticancer-mechanisms.md)
* [Redox Dual Action](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/anticancer-mechanisms/redox-dual-action.md)
* [NRF2 Impact](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/anticancer-mechanisms/nrf2-impact.md)
* [Glucose, Glutamine & the Warburg Effect](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/anticancer-mechanisms/glucose-glutamine-and-the-warburg-effect.md)
* [Berberine Evidence by Cancer Type](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/berberine-evidence-by-cancer-type.md)
* [Immune Effects](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/immune-effects.md)
* [Antimicrobial / Antifungal Activity](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/antimicrobial-antifungal-activity.md)
* [Pharmacokinetics & Metabolism](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/pharmacokinetics-and-metabolism.md)
* [Dosing & Timing](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/dosing-and-timing.md)
* [Safety & Interactions](/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/safety-and-interactions.md)

### Key References

Berberine as a Potential Anticancer Agent: A Comprehensive Review\
PMC Full Text:[ PMC8658774](https://pmc.ncbi.nlm.nih.gov/articles/PMC8658774/)

Islam MN et al. (2021). Molecules, 26(23):7368.[ PMC8658774](https://pmc.ncbi.nlm.nih.gov/articles/PMC8658774/)

Sajeev A et al. (2024). Cancer Letters, 597:217019.[ doi.org/10.1016/j.canlet.2024.217019](https://doi.org/10.1016/j.canlet.2024.217019)

Feng X et al. (2022). Evid Based Complement Alternat Med, 2022:1189034.[ PMC9316001](https://pmc.ncbi.nlm.nih.gov/articles/PMC9316001/)

Evidence-Based Complementary and Alternative Medicine (Hindawi/Wiley) — Open Access \
PMC Full Text:[ PMC9316001](https://pmc.ncbi.nlm.nih.gov/articles/PMC9316001/)

{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}

{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}


---

# Agent Instructions: Querying This Documentation

If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.

Perform an HTTP GET request on the current page URL with the `ask` query parameter:

```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/anticancer-mechanisms/ferroptosis-findings.md?ask=<question>
```

The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.

Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.